A recent brief report by MS researchers at the Kessler Foundation has provided preliminary evidence that older individuals with multiple sclerosis (MS) report lower levels of depression and higher...
Our news web pages include ground-breaking multiple sclerosis news and research from around the world.
These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.
Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.
We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years.
A recent brief report by MS researchers at the Kessler Foundation has provided preliminary evidence that older individuals with multiple sclerosis (MS) report lower levels of depression and higher...
In a recent pilot study researchers highlighted the importance of processing speed in overall cognitive function in individuals with multiple sclerosis (MS...
Results from a phase III clinical trial have revealed two years of treatment with oral Gilenya (fingolimod)...
If a person with multiple sclerosis (MS) experiences fatigue they often make several behavioural changes, such as resting and limiting activity. This...
A phase III study of statins for secondary progressive multiple sclerosis (SPMS) has begun.
Headed up by University College London Hospital Consultant Neurologist Jeremy Chataway, the trial...
The prevalence and definition of benign multiple sclerosis (BMS) remain controversial. Most definitions are based on the Expanded Disability Status Scale (EDSS), not encompassing the wider impact...
Exercise has been shown to benefit people living with multiple sclerosis (MS), but for...
The National Institute for Health and Care Excellence (NICE) has revealed it will not recommend ocrelizumab for the treatment of primary progressive...
Active Biotech has regained the global development and commercialisation rights to laquinimod from Teva Pharmaceutical Industries. Teva's decision to return the rights is based on the fact that...
...